Key Takeaways Viatris beat Q4 estimates with 57-cent EPS and $3.7B in revenue, up 5% year over year.VTRS saw 8% operational growth in Emerging Markets and Greater China, lifting Brands sales 8%.Viatris guided 2026 revenue to $14.4B-$14.9B and EPS of $2.33-$2.47 after FDA updates.Viatris Inc. (VTRS) delivered fourth-quarter 2025 adjusted earnings per share (EPS) of 57 cents, which beat the Zacks Consensus Estimate of 52 cents. The company recorded an adjusted EPS of 54 cents in the year-ago quarter.Total rev ...

Core Insights - Viatris reported strong financial results for Q4 and full year 2025, with total revenues of $3.7 billion for Q4 and $14.3 billion for the full year, meeting or exceeding financial guidance across all key metrics [1][2][3] - The company completed an enterprise-wide strategic review, expecting to deliver $650 million in total cost savings while reinvesting up to $250 million over the next three years [1][3] - Viatris anticipates regulatory decisions for six product candidates in 2026 and multiple important pipeline milestones, positioning itself for sustainable growth [1][3] Financial Performance - Q4 2025 total revenues increased by 5% compared to Q4 2024, while full year revenues decreased by 3% compared to 2024 [2][3] - U.S. GAAP net loss for Q4 2025 was $340.1 million, a 34% improvement from a loss of $516.5 million in Q4 2024 [2][3] - Adjusted net earnings for Q4 2025 were $658.7 million, with adjusted EPS of $0.57, reflecting a 6% increase from Q4 2024 [2][3] Strategic Initiatives - The company initiated restructuring activities as part of its strategic review, expecting a global workforce reduction of up to 10% [3][6] - Total pre-tax charges related to restructuring are estimated between $700 million and $850 million, with anticipated savings of $600 million to $700 million once fully implemented [3][6] - Viatris plans to provide a balanced capital allocation approach for 2026, returning over $1 billion to shareholders in 2025 [1][3] Product Pipeline and Regulatory Updates - The company generated approximately $78 million in new product revenues in Q4 2025, with expectations of $450 million to $550 million in new product revenues for 2026 [2][3] - Viatris has several regulatory submissions under review, including a J-NDA for pitolisant in Japan and an NDA for a low-dose estrogen weekly patch in the U.S. [2][6] - The FDA has assigned a PDUFA goal date of July 30, 2026, for the low-dose estrogen patch and October 17, 2026, for MR-141 [6] Market Performance - Generics net sales were impacted by competition in North America and government price regulations in Japan, while brands net sales showed strength in Greater China and Emerging Markets [2][3] - The company expects continued operational growth driven by its base business and net cost savings in 2026 [1][3]

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the top cheap stocks under $20, with recent regulatory milestones enhancing its investment appeal [1] Regulatory Milestones - The FDA approved Viatris' octreotide acetate for injectable suspension, a generic version of Sandostatin® LAR Depot, for treating acromegaly and certain types of diarrhea associated with tumors [1] - The FDA accepted the New Drug Application (NDA) for Viatris' investigational low dose estrogen weekly patch for contraception [2] - The FDA cleared the Investigational New Drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with plans for a Phase 1/2 clinical trial starting in H1 2026 [2] - The Japan Pharmaceuticals and Medical Devices Agency (PMDA) accepted the Japanese New Drug Application (J-NDA) for pitolisant in obstructive sleep apnea syndrome, with plans to submit a J-NDA for narcolepsy by year-end [3] Company Overview - Viatris is a global healthcare company providing a wide range of pharmaceutical products across various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare [4] - The company's operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets [4]